{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:59:19Z","timestamp":1781373559812,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40272-024-00637-7","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:01:37Z","timestamp":1718355697000},"page":"469-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Alirocumab: Pediatric First Approval"],"prefix":"10.1007","volume":"26","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"4","key":"637_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14712598.2024.2330948","volume":"24","author":"MD Reijman","year":"2024","unstructured":"Reijman MD, Kusters DM, Wiegman A. Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children. Expert Opin Biol Ther. 2024;24(4):243\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"637_CR2","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-015-0469-8","volume":"75","author":"A Markham","year":"2015","unstructured":"Markham A. Alirocumab: first global approval. Drugs. 2015;75(14):1699\u2013705.","journal-title":"Drugs"},{"key":"637_CR3","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron and Sanofi announce FDA approval of Praluent\u00ae (alirocumab) injection, the first PCSK9 inhibitor in the U.S., for the treatment of high LDL cholesterol in adult patients [media release]. 24 Jul 2015. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-and-sanofi-announce-fda-approval-praluentr-alirocumab\/."},{"key":"637_CR4","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron and Sanofi announce approval of Praluent\u00ae (alirocumab) for the treatment of hypercholesterolemia in the European Union [media release]. 28 Sep 2015. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-and-sanofi-announce-approval-praluentr-alirocumab\/."},{"key":"637_CR5","unstructured":"Adis Insight. Alirocumab - Regeneron\/Sanofi. 2024. https:\/\/adisinsight.springer.com\/drugs\/800031728. Accessed 17 May 2024."},{"key":"637_CR6","unstructured":"European Medicines Agency. Praluent (alirocumab). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/praluent. Accessed 17 May 2024."},{"key":"637_CR7","unstructured":"Regeneron Pharmaceuticals Inc. Praluent\u00ae (alirocumab) injection receives FDA approval to treat children with genetic form of high cholesterol [media release]. 11 Mar 2024. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/praluentr-alirocumab-injection-receives-fda-approval-treat."},{"issue":"12","key":"637_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","volume":"42","author":"E Bruckert","year":"2022","unstructured":"Bruckert E, Caprio S, Wiegman A, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol. 2022;42(12):1447\u201357.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"637_CR9","unstructured":"Regeneron Pharmaceuticals Inc. PRALUENT\u00ae (alirocumab) injection, for subcutaneous use: US prescribing information. 2024. https:\/\/www.regeneron.com\/downloads\/praluent_pi.pdf. Accessed 17 May 2024."},{"key":"637_CR10","unstructured":"European Medicines Agency. Praluent: EU summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/praluent-epar-product-information_en.pdf. Accessed 17 May 2024."},{"key":"637_CR11","unstructured":"Sanofi. Sanofi finalizes Praluent\u00ae (alirocumab) restructuring with Regeneron [media release]. 6 Apr 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-04-06-21-00-00-2012457."},{"key":"637_CR12","doi-asserted-by":"crossref","unstructured":"Regeneron. Sanofi-aventis and Regeneron expand strategic antibody collaboration [media release]. 10 Nov 2009. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/sanofi-aventis-and-regeneron-expand-strategic-antibody.","DOI":"10.3833\/pdr.v2009i11.1274"},{"key":"637_CR13","unstructured":"United States Securities and Exchange Commission. Form 10-K for Regeneron Pharmaceuticals, Inc. SEC filing report. 2023. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/872589\/000180422023000008\/regn-20221231.htm. Accessed 17 May 2024."},{"issue":"3","key":"637_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","volume":"178","author":"RD Santos","year":"2024","unstructured":"Santos RD, Wiegman A, Caprio S, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA Pediatr. 2024;178(3):283\u201393.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"637_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jacl.2020.03.001","volume":"14","author":"S Daniels","year":"2020","unstructured":"Daniels S, Caprio S, Chaudhari U, et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. J Clin Lipidol. 2020;14(3):322-30.e5.","journal-title":"J Clin Lipidol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00637-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:30:11Z","timestamp":1718951411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00637-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00637-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"14 June 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}